Literature DB >> 15604613

Uric acid elimination in the urine. Pathophysiological implications.

Martino Marangella1.   

Abstract

Uric acid, a weak organic acid, has very low pH-dependent solubility in aqueous solutions. About 70% of urate elimination occurs in urine, the kidney standing as a major determinant of plasma levels. The complex renal handling results in a fractional clearance of less than 10%. Recently identified urate-specific transporter/channels are involved in tubular handling and extracellular transport. Extracellular fluid, rather than urine output, is the main regulator of urate excretion. A number of interfering agents, including widely used drugs such as aspirin, losartan, diuretics, may decrease or increase urate elimination. Hyperuricemia induced by hypouricosuria often accompanies the metabolic syndrome, and insulin resistance has been hypothesized as the common underlying defect. Hyperuricosuria, associated with dehydration or exercise, results in acute uric acid nephropathy, and causes an obstructive acute renal failure (ARF). This reversible ARF can be prevented by forced hydration with bicarbonate or saline solutions. Renal hypouricemia, due to mutations of urate transporter, is a rare cause of exercise-induced ARF. The existence of chronic urate nephropathy, gouty nephropathy, is still under discussion. Uric acid nephrolithiasis results from supersaturation, strongly influenced by low urine pH, rather than altered urate turnover. Alkali and fluid intake prove successful in managing uric acid stones.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15604613     DOI: 10.1159/000082551

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  20 in total

1.  Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses.

Authors:  Kate Witkowska; Kyla M Smith; Sylvia Y M Yao; Amy M L Ng; Debbie O'Neill; Edward Karpinski; James D Young; Christopher I Cheeseman
Journal:  Am J Physiol Renal Physiol       Date:  2012-05-30

2.  Prevalence of hyperuricemia and its associated factors in the general Korean population: an analysis of a population-based nationally representative sample.

Authors:  Yunkyung Kim; Jihun Kang; Geun-Tae Kim
Journal:  Clin Rheumatol       Date:  2018-05-23       Impact factor: 2.980

3.  Serum uric acid: an independent predictive marker for coronary artery disease.

Authors:  Erdim Sertoglu
Journal:  Clin Rheumatol       Date:  2015-03-22       Impact factor: 2.980

4.  The Daniel K. Inouye College of Pharmacy Scripts: Perspectives on the Epidemiology of Gout and Hyperuricemia.

Authors:  Youssef M Roman
Journal:  Hawaii J Med Public Health       Date:  2019-02

5.  Increased prevalence of simple renal cysts in patients with gout.

Authors:  Eduardo Massato Hasegawa; Ricardo Fuller; Maria Cristina Chammas; Filipe Martins de Mello; Claudia Goldenstein-Schainberg
Journal:  Rheumatol Int       Date:  2012-03-28       Impact factor: 2.631

6.  Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey.

Authors:  Jeffrey C Sirota; Kim McFann; Giovanni Targher; Richard J Johnson; Michel Chonchol; Diana I Jalal
Journal:  Metabolism       Date:  2012-10-02       Impact factor: 8.694

7.  Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010.

Authors:  Stephen P Juraschek; Lara C Kovell; Edgar R Miller; Allan C Gelber
Journal:  Semin Arthritis Rheum       Date:  2013-01-09       Impact factor: 5.532

Review 8.  Uric acid: a novel mediator and marker of risk in chronic kidney disease?

Authors:  Daniel I Feig
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-11       Impact factor: 2.894

9.  Asymptomatic kidney stones in long-term survivors of childhood acute lymphoblastic leukemia.

Authors:  S C Kaste; N A Thomas; S N Rai; K Cheon; E McCammon; R Chesney; D Jones; C-H Pui; M M Hudson
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528

10.  Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.

Authors:  Charlotte Andersson; Peter Weeke; Bente Brendorp; Lars Køber; Emil L Fosbøl; Arya M Sharma; Nick Finer; Ian D Caterson; Richard A Rode; Philip T James; Christian Torp-Pedersen
Journal:  Nutr Metab (Lond)       Date:  2009-10-14       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.